By
Drug Target Review2025-09-02T09:00:00
With over 1,000 skin diseases lacking approved treatments, a search-and-develop model is changing how new therapies are sourced and developed. Chief Scientific Officer, Jacob Pontoppidan Thyssen, outlines the strategy behind it.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2023-05-23T11:10:47
Sponsored by NanoTemper Technologies
2024-02-01T12:06:43
Sponsored by Leica Microsystems
2025-11-13T14:00:00
Sponsored by Cell Signaling Technology
2024-02-06T08:57:06
Sponsored by bit.bio
2023-02-13T11:57:11
Sponsored by Agilent
2025-04-02T14:00:00
Sponsored by Eurofins Discovery
Site powered by Webvision Cloud